Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 6/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMO | Q99835 | 2/20 | 0.41 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7137826 | 0.89 | TACR1 (0.47) | TACR1L3MBTL1CYP1A2ALDH1A1SMO | |
| SCHEMBL905365 | 0.88 | TACR1 (0.49) | TACR1L3MBTL1CYP1A2SMOGPBAR1 | |
| SCHEMBL905377 | 0.88 | TACR1 (0.45) | TACR1L3MBTL1CYP1A2SMOGPBAR1 | |
| SCHEMBL905379 | 0.88 | CYP1A2 (0.54) | TACR1CYP1A2CYP2C19ALDH1A1RAB9A | |
| SCHEMBL7558999 | 0.87 | TACR1 (0.56) | TACR1L3MBTL1CYP1A2CYP2C19MEN1 | |
| SCHEMBL14575924 | 0.87 | TACR1 (0.44) | TACR1L3MBTL1CYP1A2HTR3ARAB9A | |
| SCHEMBL29514441 | 0.86 | TACR1 (0.59) | TACR1L3MBTL1CYP1A2CYP2C19MEN1 | |
| SCHEMBL1399329 | 0.86 | TACR1 (0.59) | TACR1L3MBTL1CYP1A2CYP2C19MEN1 | |
| SCHEMBL905358 | 0.86 | HTR3A (0.49) | TACR1L3MBTL1CYP1A2CYP2C19MEN1 | |
| SCHEMBL4672291 | 0.85 | TACR1 (0.43) | TACR1L3MBTL1ALDH1A1CYP3A4SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282729-A1 | CHEMICAL COMPOUND MANUFACTURE, NEW SALT FORM, AND THERAPEUTIC USES THEREOF | EUSTRALIS PHARMACEUTICALS LIMITED (TRADING AS PRESSURA NEURO) (AU) | 2025-09-11 | — | — | US | disclosed |
| US-12351557-B2 | Chemical compound manufacture, new salt form, and therapeutic uses thereof | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2025-07-08 | — | — | US | disclosed |
| US-20220073467-A1 | Chemical Compound Manufacture, New Salt Form, And Therapeutic Uses Thereof | EUSTRALIS PHARMACEUTICALS LIMITED (TRADING AS PRESSURA NEURO) (AU) | 2022-03-10 | — | — | US | disclosed |
| EP-3902793-A1 | CHEMICAL COMPOUND MANUFACTURE, NEW SALT FORM, AND THERAPEUTIC USES THEREOF | Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) (AU) | 2021-11-03 | — | — | EP | disclosed |
| WO-2020132716-A1 | CHEMICAL COMPOUND MANUFACTURE, NEW SALT FORM, AND THERAPEUTIC USES THEREOF | EUSTRALIS PHARMACEUTICALS LIMITED (TRADING AS PRESSURA NEURO) (AU) | 2020-07-02 | — | — | WO | disclosed |
| WO-2020132716-A1 | CHEMICAL COMPOUND MANUFACTURE, NEW SALT FORM, AND THERAPEUTIC USES THEREOF | EUSTRALIS PHARMACEUTICALS LIMITED (TRADING AS PRESSURA NEURO) (AU) | 2020-07-02 | — | — | WO | disclosed |
| EP-1394150-B1 | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists | HOFFMANN LA ROCHE (CH) | 2011-01-19 | — | — | EP | disclosed |
| CN-100346789-C | Use of nk-1 receptor antagonists for the treatment of brain, spinal or nerve injury | HOFFMANN LA ROCHE (CH) | 2007-11-07 | — | — | CN | disclosed |
| CN-1523988-A | Use of nk-1 receptor antagonists for the treatment of brain, spinal or nerve injury | - | 2004-08-25 | — | — | CN | disclosed |
| EP-1394150-A1 | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-03 | — | — | EP | disclosed |
| EP-1103546-B1 | Process for preparation of pyridine derivatives | HOFFMANN LA ROCHE (CH) | 2003-10-22 | — | — | EP | disclosed |
| US-6479483-B2 | 3,4,6-SUBSTITUTED PYRIDINE DERIVATIVES USEFUL FOR TREATING DEPRESSION AND PAIN, RESULTING FROM INFLAMMATORY CONDITIONS, SUCH AS MIGRAINE, RHEUMATOID ARTHRITIS, ASTHMA AND INFLAMATORY BOWEL DISEASE; NK1 RECEPTOR ANTAGONIST | HOFFMANN-LA ROCHE INC. | 2002-11-12 | — | — | US | disclosed |
| US-20020091265-A1 | 4-phenyl-pyridine derivatives | BOS MICHAEL (CA) | 2002-07-11 | — | — | US | disclosed |
| US-6303790-B1 | REACTING SUBSTITUTED NICOTINAMIDE WITH GRIGNARD REAGENT, OXIDIZING PRODUCT, REACTING WITH HALO-SUBSTITUTED AROMATIC COMPOUND | HOFFMAN-LA ROCHE INC. | 2001-10-16 | — | — | US | disclosed |
| US-6297375-B1 | 4-phenyl-pyridine derivatives | HOFFMANN-LA ROCHE INC. | 2001-10-02 | — | — | US | disclosed |
| EP-1103546-A1 | Process for preparation of pyridine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2001-05-30 | — | — | EP | disclosed |
| EP-1035115-A1 | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2000-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282729-A1 | CHEMICAL COMPOUND MANUFACTURE, NEW SALT FORM, AND THERAPEUTIC USES THEREOF | SCN5A, MGMT, NISCH | TACR1 564/4885L3MBTL1 4373/4885CYP1A2 570/4885 |
| US-20020091265-A1 | 4-phenyl-pyridine derivatives | CBR1, CBR3, HCCS | TACR1 534/4885L3MBTL1 1978/4885CYP1A2 1297/4885 |
| US-12351557-B2 | Chemical compound manufacture, new salt form, and therapeutic uses thereof | SCN5A, MGMT, NISCH | TACR1 564/4885L3MBTL1 4373/4885CYP1A2 570/4885 |
| US-20220073467-A1 | Chemical Compound Manufacture, New Salt Form, And Therapeutic Uses Thereof | SCN5A, MGMT, NISCH | TACR1 564/4885L3MBTL1 4373/4885CYP1A2 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.